Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics - Results from the Phase III FlashLyte Study

1. Blaettler, T.
2. Bugarski-Kirola, D.
3. Fleischhacker, W.W.
4. Bressan, R.
5. Arango, C.
6. Abi-Saab, D.
7. Napieralski, J.
8. Dixon, M.
9. Marder, S.